Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant‐Eligible and Ineligible Acute Myeloid Leukemia
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.03.2026. Verfasst von Takafumi Tsushima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan. Hauptthemen laut MEDLINE: Muramidase, Leukemia, Myeloid, Acute, Acute Kidney Injury, Kidney. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lysozyme‐induced nephropathy is a complication of chronic myelomonocytic leukemia and acute myeloid leukemia (AML). Few studies have discussed the association between blood lysozyme levels at AML onset and AML prognosis, which this study aimed to address. A total of 166 AML patients (72 transplant‐eligible and 94 transplant‐ineligible cases) undergoing chemotherapy at our hospital with recorded serum lysozyme levels were retrospectively included between March 2012 and March 2024. The median age, creatinine, and serum lysozyme at diagnosis were 65 (22–86) years, 0.85 mg/dL (0.43–3.56), and 16.4 μg/mL (0.3–560.0), respectively. Hematopoietic stem cell transplantation was performed in 43.4% of all patients. At initial diagnosis, the lysozyme and creatinine levels were positively correlated (the Spearman rank correlation coefficient: +0.516, p < 0.05). Using ROC analysis, the optimal serum lysozyme cutoff values for predicting AKI (KDIGO > 0) at AML onset were determined to be 22.4 μg/mL (AUC, 0.89: 95% CI: 0.847–0.951). The two‐year overall survival (OS) did not differ significantly between patients with lysozyme < 22.4 μg/mL and patients with lysozyme ≥ 22.4 μg/mL (two‐year OS, 39.5% vs. 42.2% [95% CI, 29.2%–49.6% vs. 29.8%–54.1%]; p = 0.862). The same trend was observed in the transplantation group. After remission induction, most patients with high‐lysozyme levels showed creatinine level recovery (AML onset: median 1.15 mg/dL, 1 month later: median 0.72 mg/dL, 3 months later: median 0.65 mg/dL). The effect of lysozyme levels on prognosis is limited because renal function recovers in many patients with high‐lysozyme levels after chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
ORCID-Profile: Takafumi Tsushima
Zitieren
APA
Tsushima, T., Matsuo, K., Shoji, A., Kimeda, C., Matsumoto, R., Shimoji, S., Utsu, Y., Masuda, S. I., & Aotsuka, N. (2026). Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant‐Eligible and Ineligible Acute Myeloid Leukemia. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71741
Vancouver
Tsushima T, Matsuo K, Shoji A, Kimeda C, Matsumoto R, Shimoji S, et al. Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant‐Eligible and Ineligible Acute Myeloid Leukemia. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71741
BibTeX
@article{Tsushima2026,
author = {Tsushima, Takafumi and Matsuo, Kosuke and Shoji, Akihiro and Kimeda, Chiharu and Matsumoto, Rena and Shimoji, Sonoko and Utsu, Yoshikazu and Masuda, Shin-Ichi and Aotsuka, Nobuyuki},
title = {Impact of High Serum Lysozyme Activity on Renal Function and Survival Outcomes in Transplant‐Eligible and Ineligible Acute Myeloid Leukemia},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71741}
}
EUVIMED